PSA retesting interval can be individualized

Middle-aged men with an initial prostate specific antigen (PSA) level of less than 1 can safely wait for 3 years before repeating the PSA test, a study suggests, while those with PSA levels greater than 1.5 should probably undergo repeat testing every year.

It’s currently common practice for middle-aged men to be screened for Prostate cancer with the PSA test annually. The current study findings, say researchers, hint that the PSA screening interval can be individualized based on the initial PSA result.

Dr. Gunnar Aus, from Sahlgrens University Hospital in Goteborg, Sweden, and colleagues followed 5855 randomly selected men initially tested at ages 50 to 66 years in 1995 or 1996.

If their PSA value was 3 or higher, they were offered prostate biopsies. Otherwise, the initial test was followed by repeat PSA testing every two years.

A total of 539 men developed Prostate cancer during the roughly 7 years they were followed, the study team reports in the current Archives of Internal Medicine.

There were no cases of the disease diagnosed among men with PSA values less than 0.5. The risk of prostate cancer was 0.9 percent for those with levels between 0.50 and 0.99, 4.7 percent for those with levels between 1.0 and 1.49, and 12.3 percent for those with levels of 1.5 to 1.99. The risk of prostate cancer rose steadily thereafter to a 76.8 percent risk among those with PSA levels of 10 or higher.

During the first 3 years after the initial PSA test, there were no cases among men with a first-time PSA level of 0.5 to 0.99 and only three cases among those with first-time levels of 1.00 to 1.49.

The authors conclude, based on their findings, that PSA retesting intervals “should be individualized” on the basis of the initial PSA level. The “large group of men” with PSA levels less than 1 can safely be retested every 3 years, they say.

They recommend annual testing for those with PSA levels greater than 1.5.

SOURCE: Archives of Internal Medicine, September 12, 2005. 

RELATED STORIES:
Delay OK before radiation for prostate cancer   Pros and cons with “easier” prostate cancer surgery   Prostate Cancer: Watchful Wait or Vaccinate?   Prostate Cancer Patients Sought for Database as Part of Joint Effort   Discovery of a new virus in prostate tumors   Common Genetic Risk Factor for Colorectal and Prostate Cancer Identified   Radiation therapy technique reduces length of prostate cancer treatment   Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients   Prostate Cancer Genes Behave Like Those in Embryo   Study looks at using the immune system to reduce prostate cancer risk   Selenium Intake May Worsen Prostate Cancer in Some   Cigarette smoking may raise prostate cancer risk   Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy   Study links obesity to more agressive prostate cancer   Exercise Reduces Death Rate in Prostate Cancer Patients   Vaccine Approach Extends Life of Metastatic Prostate Cancer Patients   First Biomarker Discovered that Predicts Prostate Cancer Outcome   ARRA Funds Research to Improve Prostate Cancer Identification   Turmeric holds real potential for the treatment and prevention of prostate cancer   New Approach for Treating Recurrent Prostate Cancer on the Horizon   Obesity-linked High Blood Volumes Render PSA Prostate Cancer Test Less Effective   Prostate surgery risks lower at academic hospitals

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]